Kymera Therapeutics (KYMR) PT Raised to $140 at JPMorgan

September 2, 2026 9:22 AM

JPMorgan analyst Brian Cheng raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $140.00 (from $121.00) while maintaining a Overweight rating.

No results found